HLA-B39 (B39) is an HLA-B serotype. The serotype identifies the more common HLA-B*39 gene products. [1] B39 is a split antigen of the broad antigen B16, and is a sister type of B38. B39 is most commonly found on the west pacific rim, in Japan and highest frequency in the new world. In Europe it is found in Scandinavia and Northern Russia.

HLA-B39 alone, HLA-B27 only in the presence of HLA-DR7, and HLA-DQ3 only in the absence of HLA-DR7, conferred an increased risk for disease progression [55]. The ‘rheumatoid arthritis (RA) shared epitope’ was found to be associated with radiographic erosions [56] .

Of these, HLA-B*39:06 is the HLA-B allele most associated with disease progression; it is also associated with an early age of disease onset (Howson et al. 2009; Nejentsev et al. 2007; Noble et al. 2010).

B39 is a split antigen of the broad antigen B16, and is a sister type of B38. B39 is most commonly found on the west pacific rim, in Japan and highest frequency in the new world. In Europe it is found in Scandinavia and Northern Russia.

We report here that an Nα -acetylated peptide is a natural ligand of HLA-B39. This is, to our knowledge, the first known N -acetylated ligand of any class I molecule, and the first natural ligand with a blocked NH 2 terminus reported from a classical MHC class I protein.

The HLA-B*39:01:01:31 allele differs from HLA-B*39:01:01:03 by a single nucleotide substitution in intron 2. Keywords: HLA‐B*39:01:01:31; HLA‐genotyping; illumina; next generation sequencing; novel allele.

Jul 6, 2020 · HLA-B39 subtypes were determined by polymerase chain reaction-sequence-specific oligohybridization. Results: HLA-B27 was present in 40 of 48 patients with AS (83%), and in only 1 of 210 healthy controls (0.5%).

The frequency distribution of HLA-B38 and HLA-B39 was studied in a group of 50 unrelated psoriatic arthritis patients. A high increase of HLA-B39 was noted in the subgroup with axial arthropathy. All B39 positive patients presented with spondylitis and/or sacroiliitis.

Serological studies have suggested the presence of a new HLA-B39 subtype (B39.2) in the Japanese population. To identify the new HLA-B39 subtype and compare it with an other HLA-B39 subtype ( B39.1 ), the genes encoding HLA-B39.1 ( B * 39013) and B39.2 (B * 3902) have been cloned from Japanese.

HLA‐B39 subtypes were determined by polymerase chain reaction‐sequence‐specific oligohy‐bridization. Results. HLA‐B27 was present in 40 of 48 patients with AS (83%), and in only 1 of 210 healthy controls (0.5%).